Laurance Johnston, Ph.D.


Agarwal S, Rao AV, “Tomato lycopene and its role in human health and chronic diseases.” CMAJ 163 (6), September 19, 2000, pp. 739-744.

Badmaev V, Majeed M, Paswater RA, “Selenium: a quest for better understanding,” Alternative Therapies in Medicine, 2 (4), July 1996, pp.59-62.

Blumenfeld AJ, Fleshner N, Casselman B., Trachtenberg J., “Nutritional aspects of cancer; a review,” Canadian Journal of Urology, 7 (1), February 2000, pp. 927-935.

Chan JM, Giovannucci E, Anderson SO, Yuen J, Adami HO, Wolk A, “Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden),” Cancer Causes Control, 9 (6), December 1998, pp. 559-566.

Chan JM, Stampfer MJ, Giovannucci EL, “What causes prostate cancer? A brief summary of the epidemiology,” Seminars Cancer Biology,  8 (4) pp. 263 –273.

Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL.,  “Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States,” Cancer Epidemiology Biomarkers and Prevention, 8 (10), October 1999, pp. 893 –899.

Clark LC, Dalkin B, Krongrad, A, Combs GF, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J, “Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial,” British Journal of Urology, 81 (5), May 1998, pp. 730-734.

Clinton SK, Emenhiser, C, Schwartz SJ, Bostwick DG, Williams AW, Moore BJ, Erdman JW, “Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate,” Cancer Epidemiology Biomarkers and Prevention, 5 (10), October 1996, pp. 823-833.

Clinton SK, “Lycopene: chemistry, biology, and implications for human health and disease,” Nutrition Reviews, 56 (2 Pt 1), February 1998, pp. 35-51.

Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH, “Inhibition of prostate specific antigen expression by geistein in prostate cancer,” International Journal of Oncology, 16 (6), June 2000, pp. 1091-1097.

Fahim MS, Wang M, Sutcu MF, Fahim Z., “Zinc arginine, a 5 alpha-reductase inhibitor, reduses rat ventral prostate weight and DNA without affecting testicular function,” Andrologia, 25 (6), November-December, 1993, pp. 369-375.

Fair WR, Fleshner NE, Heston W, “Cancer of the prostate: a nutritional disease,” Urology, 50 (6), December 1997, pp. 840-848.

Fleshner NE, Klotz LH, “Diet, androgens, oxidative stress and prostate cancer susceptibility,” Cancer Metastasis Review, 17 (4), 1998-1999, pp. 325-330.

Gallia K, “Lycopene: In addition to protecting the prostate, this antioxidant prevents heart disease and may slow the aging process,” Natural Health, October 1999, p. 43.

Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ, “Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis,” Cancer Research, 59 (6), March 15, 1999, pp. 1225-1230.

Gerster H, “The potential role of lycopene for human health,” Journal American College of Nutrition, 16 (2) pp. 109-126.

Giles G., Ireland P, “Diet, nutrition and prostate cancer,” International Journal of Cancer, supplement 10, 1997, pp. 13-17.

Giovannucci E, “How is individual risk for prostate cancer assessed?” Hematology/Oncology Clinics of North America, 10 (3), June 10, 1996, pp.537-548.

Giovannucci E, “Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature,” Journal National Cancer Institute, 91 (4), February 17, 1999, pp. 317-331.

Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, “Intake of carotenoids and retinol in relation to risk of prostate cancer,” Journal National Cancer Institute, 87 (23), December 6, 1995, pp. 1767-1776.

Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC, “ Calcium and fructose intake in relation to risk of prostate cancer,” Cancer Research, 58 (3), February 1, 1998, pp. 442-447.

Grant WB, “An ecologic study of dietary links to prostate cancer,” Alternative Medicine Review, 4 (3), pp. 162-169.

Gunawardena K, Murray DK, Meikle AW, “vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis,” Prostate 44 (4), September 1, 2000, pp.287-295.

Guttenplan JB, Chen M, Kosinska W. thompson S, Cohen LA, “Effects of a lycopene-rich diet on spontaneous and benzo,” Cancer Letters, 164 (1), March 10, 2001, pp. 1-6.

Hayes RB, Ziegler RG, Gridley G, Swanson C. Greenberg RS, Swanson GM, Schoenberg JB, Silverman DT, Brown LM, Pottern LM, Liff J, Schwartz AG, Fraumeni JF, Hoover RN., “Dietary factors and risks for prostate cancer among blacks and whites in the United States,” Cancer Epidemiology Biomarkers and Prevention, 8 (1), January 1999, pp.25-34.

Habito RC, Montalto J, Leslie E., Ball MJ, “Effects of replacing meat with soybean in the diet on sex hormone concentrations in healthy adult males,” British Journal of Nutrition,  84 (4), October 2000 pp. 557-563.

Kapur S, “ A medical hypothesis: phosphorous balance and prostate cancer,” Cancer Investigations, 18 (7), 2000, pp. 664-669.

Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT, “A case-control study of diet and prostate cancer,” British Journal of Cancer, 76 (5), 1997, pp. 678-687.

Kristal AR, Stanford JL, Cohen JHJ, Wicklund K, Patterson RE, “Vitamin and mineral supplement use is associated with reduced risk of prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, 8 (10), October 1999, pp. 887-892.

Kumar NB, Besterman-Dahan K, “Nutrients in the chemoprevention of prostate cancer: current and future prospects,” Cancer Control, 6 (6), November 1999, pp. 580-586.

Lagiou P, Wuu J, Trichopoulou A, Hsieh CC, Adami HO, Trichopoulos D, “Diet and benign prostatic hyperplasia; a study in Greece,” Urology, 54 (2), August 1999, pp. 284 – 290.

Leake A., Chrisholm GD, Busuttil A, Habib FK, “ Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction,” Acta Endocrinology Copenhagen, 105 (2), February 1984, pp. 281-288.

Leake A, Chisolm GD, Habib FK, “The effect of zinc on the 5 alpha-reduction of testosterone by the hyperplastic human prostate gland,” Journal of Steroid Biochemistry, 20 (2), February 1984, pp.651-655.

Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P, “Inhibitory effect of zinc on human prostatic carcinoma cell growth, Prostate, 40 (3), August 1999, pp. 200–207.

Menter DG, Sabichi AL, Lippman SM, “Selenium effects on prostate cell growth,” Cancer Epidemiology Biomarkers and Prevention, 9 (11), November 2000, pp. 1171-1182.

Mills PK, Beeson WL, Phillips RL, Fraser GE, “Cohort study of diet, lifestyle, and prostate cancer in Adventist men,” Cancer, 64 (3), August 1, 1989, pp. 598-604.

Nelson MA, Porterfield BW, Jacobs ET, Clark LC, “Selenium and prostate cancer prevention,” Seminar in Urology and Oncology, 17 (2), May 1999, pp. 91-96.

Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM, “Men who consume vegetable oils rich in monosaturated fat; their dietary patterns and risk of prostate cancer (New Zealand),” Cancer Causes Control 11 (7), August 2000, pp. 609-615.

Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM, “Prostate cancer and dietary carotenoids,” American Journal of Epidemiology, 151 (2), January 15, 2000, pp. 119-123.

Oldereid NB, Thomassen Y, Purvis K, “Selenium in human reproductive organs,” Human Reproduction, 13 (8), August 1998, pp.2172-2176.

Pastori, M, Pfander H, Boscoboinik D, Azzi A, “Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate cancer cells,” Biochemical and Biophysical Research Communications, 250 (3), September 29, 1998, pp. 582-585.

Pinto, JT, Qiao C, Xing J, Rivlin RS, Protomastro ML, Weissler ML, Tao Y, Thaler, Heston WD, “Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture," American Journal of Clinical Nutrition, 66 (2), August 1997, pp 389-405.

Pinto JT, Qiao C, Xing J, Suffoletto BP, Schubert KB, Rivlin RS, Huryk RF, Bacich, DJ, Heston WD, “alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allymercaptocysteine,” Prostate, 45 (4), December 1, 2000, pp. 304-314.

Pollard M, Wolter W, “Prevention of spontaneous prostate-related cancer in lobund-wistar rats by a soy protein isolate/isoflavone diet,” Prostate, 45 (2), October 1, 2000.

Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, Lynch CF, “Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men,”  Ann. Epidemiology, 10 (6), August 2000, pp. 361-369.

Sigounas G, Hooker J, Anagnostou A, Steiner M, “ S-allymercaptocysteine inhibits cell proliferation and reduces the viability of erythroleukemia, breast, and prostate cancer cell lines,” Nutrition and Cancer, 27 (2), 1997, pp. 186-191.

Stahl W, Sies H, “Lycopene: a biologically important carotenoid for humans?” Archives Biochemistry and Biophysics, 336 (1), December 1, 1996, pp. 1-9.

Thomas JA, “Diet, micronutrients, and the prostate gland,” Nutrition Reviews, 57 (4), April 1997, pp. 95-103.

Urban D, Irwin W., Kirk M, Markiewicz MA, Myers R, Smith M, Weiss H, Grizzle WE, Barnes, S, “The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen,” Journal Urology,  165 (1), January, 20001, pp. 294–300.

Wong YC, Wang YZ, Lee JS, Tam NN, Lee D, “changes in serum and tissue zinc levels in sex hormoe-induced prostatic carcinogenesis in the noble rat,” Tumour Biology, 21 (6), November-December 2000, pp. 328-336.

Yoshizawa K, Willet WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E, “ Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer,” Journal of the National Cancer Institute, 90 (16), August 19, 1998, pp. 1219-1224.

Zand RS, Jenkins DJ, Diamandis EP, “Steroid hormone activity of flavanoids and related compounds,” Breast Cancer Research Treatments,” 62 (1), July 2000, pp. 35-49.

Zhao X, Feldman D, “The role of vitamin D in prostate cancer,” Steroids, 66 (3-5), March 2001, pp. 293-300.


Breza J, Dzurny O, Borowka A, Hanus T, Petric R, Blane G, Chadha-Boreham H, “Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe,” Current Medical Research and Opinion, 14 (3), 1998, pp. 127-139.

Buck AC, Rees RWM, Ebeling L, “Treatment of chronic prostatitis and prostatodynia with pollen extract,” British Journal of Urology, 64, 1989, pp. 496-499.

Buck AC, Rees RWM, Ebeling L, John A, “Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study,” British Journal of Urology 66, 1990, 398-404.

Cristoni A, Di Pierro F, Bombardelli E., “Botanical derivatives for the prostate,” Fitoterapia, 71, Supplement 1, August 2000, pp. 21-28.

Chatelain C, Autet W. Brackman F., “Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-tern open label extension.” Urology, 54 (3), September 1999, pp. 473-478.

Dutkiewicz S, “ Usefulness of Cernilton in the treatment of benign prostatic hyperplasia,” International Urology and Nephrology, 28 (1), 1996 pp. 49-53.

Habib FK, Ross M, Lewnstein A, Zhang X, Jaton JC, “Identification of a prostate inhibitory substance in a pollen extract,” Prostate 26 (3), march 1995, pp. 133-139.

Ishani A. MacDonald R, Nelson D, Rutka I, Wilt TJ, Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis,” American Journal of Medicine109 (8), December 1, 2000, pp.654-664.

Levin RM, Das AK, “A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens,” Urological Research, 28(3), June 2000, pp. 201-209.

Lichius JJ, Renneberg H, Blaschek W, Aumuller G, Muth C, “ The inhibiting effects of components of stinging nettle roots on experimentally induced prostatic hyperplasia in mice,” Planta Medica, 5 (7), October 1999, pp.666-668.

Loschen G, Ebeling L, “Inhibition of the arachidonic acid metabolism by an extract from rye pollen ,” Arzneimittel-Forshung, 41 (1), 1992, pp. 162-167.

MacDonald R, Ishani A, Rutks I, Wilt TJ, “A systematic review of Cernilton for the Treatment of benign prostatic hyperplasia,” British Journal of Urology International, 85 (7), May 2000, pp.836-841.

Murray MT, “The Healing Power of Herbs;” published by Prima Health, 1995.

Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B,  “Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition, “ Prostate 22 (1), 1993 pp. 43-51.

Romics I, “Observations with Bazoton in the management of prostatic hyperplasia,” International Urology and Nephrology, 19 (3), 1987, pp. 293-297.

Rugendorff EW, Weidner W, Ebeling L, Buck AC, “Results of Treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia,” British Journal of Urology, 71 (4), April 1993, pp.433-438.

Sandoval A, “Pygeum for prostate health,” Natural Health, September 2000, p. 42.

Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C., “Saw Palmetto extracts for treatment of benign hyperplasia,” Journal of the American Medical Association, 280 (18), November 11, 1998, pp.1604-9.

Wilt TJ, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J,  “Serena repens for benign prostatic hyperplasia,” Cochrane Database of Systematic Reviews, 2000.

Wilt T, MacDonald R, Ishani A, Rutks I, Stark G., “Cernilton for benign prostatic hyperplasia,” Cochrane Database of Systematic Reviews, 2000.